Research & Regulatory News
Comparing an Operation With an Injection
Sabatella and colleagues published a network meta-analysis of randomised controlled trials comparing metabolic and bariatric surgery against GLP-1 receptor agonists in Obesity in April 2026 — an indirect comparison, because the two are rarely randomised against each other.
Key facts
- Study
- Sabatella 2026 (PMID 41326176)
- Journal
- Obesity (Silver Spring), April 2026
- Method
- Network meta-analysis of RCTs
- Comparison
- Metabolic/bariatric surgery vs GLP-1 RAs
- Why indirect
- Direct randomisation is rare
- Key limitation
- Transitivity across dissimilar trials
Why the comparison is asked
Bariatric surgery has produced substantial and durable weight reduction for decades, with long-term outcome data no medicine can yet match. Incretin therapies now produce reductions approaching what surgery achieves. Whether an operation remains necessary is therefore a genuine clinical question rather than a rhetorical one.
Why randomising the two directly is rare
Blinding is impossible, recruitment is difficult because participants usually have a strong preference, and equipoise is hard to establish. A trial randomising someone to surgery or an injection asks them to accept an outcome they may find unacceptable, which is why so few such trials exist and why indirect methods are used instead.
Research material referenced
Retatrutide 10mg — third-party HPLC tested
What a network meta-analysis contributes here
It links surgical trials and drug trials through comparators they share, producing an indirect estimate with propagated uncertainty. That is more disciplined than reading the two literatures side by side, and it remains an indirect estimate resting on the assumption that the linked trials are comparable.
Why transitivity is strained in this particular comparison
Surgical trials and drug trials differ systematically. Surgical candidates typically have higher baseline BMI. Follow-up in surgical literature runs to years or decades where drug trials run to 68 or 72 weeks. Comparators differ. Those are precisely the differences that make linking through a common arm questionable, and they should be examined rather than assumed away.
The dimension weight percentage does not capture
Durability and reversibility. Surgery is permanent and its effect persists without ongoing adherence; a medicine works while taken and weight returns when it stops. Two interventions producing the same percentage at one timepoint are not equivalent if one requires indefinite continuation and the other does not.
What this does not concern
Research material. This compares a surgical procedure with licensed medicines, both delivered under clinical supervision. Nothing supplied on this site is a GLP-1 receptor agonist, an alternative to surgery, or relevant to any treatment decision.
Extended research context
The Research & Regulatory News deep dive
Deep dive: why 2026 was the year the incretin field split in two
For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.
Deep dive: what a marketing authorisation actually means
An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.
Deep dive: reading trial results without being misled
Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.
Research applications
- ▸Tracking regulatory status of investigational incretin compounds
- ▸Understanding the difference between authorisation, NICE appraisal and NHS availability
- ▸Comparing peptide and non-peptide receptor agonist pharmacology
- ▸Interpreting Phase 3 topline releases before peer-reviewed publication
- ▸Verifying trial identity against ClinicalTrials.gov registrations
Handling checklist
- ✓Check the compound named in a trial registration matches the compound being discussed
- ✓Confirm the NCT identifier resolves to the acronym being cited
- ✓Read topline press releases as preliminary until peer-reviewed publication
- ✓Separate the trial population from the headline percentage before comparing studies
- ✓Treat authorisation in one jurisdiction as saying nothing about status in another
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Treating a positive Phase 3 as approval
Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.
✗ Comparing weight-reduction percentages across different trials
Fix: Population, duration and comparator differ; the numbers are not interchangeable.
✗ Assuming one incretin's approval legitimises another compound
Fix: Authorisations are product-specific and do not transfer between compounds.
✗ Citing a TRIUMPH number without checking the NCT identifier
Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.
✗ Reading research material as an alternative to a licensed medicine
Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Is orforglipron a peptide?
- Has retatrutide been approved by the MHRA?
- What did TRIUMPH-1 actually report?
- Why can orforglipron be taken as a tablet when peptides cannot?
- Are research peptides legal in the UK?
- What is the difference between MHRA authorisation and NHS availability?
Frequently asked questions
- Why not randomise surgery against a drug directly?
- Blinding is impossible, participants usually have strong preferences, and equipoise is hard to establish — so few such trials exist.
- What does the network method add?
- It links surgical and drug trials through shared comparators with propagated uncertainty — more disciplined than reading the literatures side by side.
- What does a weight percentage miss?
- Durability and reversibility. Surgery persists without ongoing adherence; a medicine works while taken.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedSabatella L et al., Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP-1 Receptor Agonists: A Network Meta-Analysis of Randomized Controlled Trials — Obesity 2026 (PMID 41326176)pubmed.ncbi.nlm.nih.gov
- PubMedFrederiksen KD et al., Bone structural changes after gastric bypass surgery evaluated by HR-pQCT — Calcif Tissue Int 2016 (PMID 26661530)pubmed.ncbi.nlm.nih.gov
- RefSURMOUNT-5: Tirzepatide as compared with semaglutide — NEJMnejm.org
- RefMHRA · Medicines and Healthcare products Regulatory Agencygov.uk
- RefNICE · National Institute for Health and Care Excellencenice.org.uk
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066) — Retatrutide pivotal obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · ATTAIN-1 (NCT05869903) — Orforglipron in obesity/overweightclinicaltrials.gov
- RefEli Lilly · TRIUMPH-1 topline results (May 2026)investor.lilly.com
- PubMedOrforglipron: A Comprehensive Review — Int J Mol Sci 2026 (PMID 41683830)pubmed.ncbi.nlm.nih.gov
- RefMHRA Yellow Card — report a defective or falsified medicineyellowcard.mhra.gov.uk
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More Research & Regulatory News articles
- Does Amylin Need a GLP-1 Partner?CagriSema pairs amylin with semaglutide and missed non-inferiority. A 2026 review surveys long-acting amylin peptides being developed on their own.
- The Trial Where Glucose-Dependence Shows Up in Numbers2,002 randomised, 52 weeks. Hypoglycaemia 6–9% with tirzepatide against 19% with glargine — and 1–3% versus 16% without a sulfonylurea.
- TRIUMPH-4: The First Retatrutide Phase 3 to Read OutTRIUMPH-4 randomised 445 adults with obesity and knee osteoarthritis. Co-primary endpoints, two estimands, and a pain result that did not track the dose.
- VESPER: What Is Actually Registered for BerobenatideSix VESPER trials, from a 239-person Phase 2b to a 3,578-person Phase 3. Registry records, enrolment, completion dates, and which acronyms are registered.
- SOLIS-1: Testing Two Compounds and Their Combination at OnceSOLIS-1 is a Phase 2b umbrella study of an estimated 872 participants, testing an amylin analogue, an ultra-long-acting GLP-1 agonist, and both in combination.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchIs Retatrutide FDA Approved? Regulatory Status Explained
- GHK-Cu (Copper Peptide)The 4,000 Genes Claim, Examined
- TB-500 (Thymosin β4 fragment)LKKTETQ: The Actin-Binding Motif
- BPC-157 (Pentadecapeptide)BPC-157 vs TB-500 Compared
- CJC-1295 & IpamorelinWhat Is Ipamorelin? A Complete Research Overview
- Peptide ReferenceNet Peptide Content: The Number That Says How Much You Have
- Bacteriostatic WaterHow Benzyl Alcohol Works as a Preservative
- GLP-1 & Incretin ScienceDPP-4: Why Native Incretins Last Two Minutes
- MOTS-c (Mitochondrial Peptide)Why Mitochondrial Genetics Is Not Like Nuclear Genetics
- Semax (ACTH Fragment Peptide)What the Melanocortin Neuroprotection Literature Reports
- Selank (Tuftsin Analogue)Tuftsin and the Antigenicity Question
- DSIP (Delta Sleep-Inducing Peptide)DSIP Regulatory Status
- KLOW (Blend)KPV: The Component With a Different Parent
- GLOW (Blend)The Two Repair-Literature Components
- MT-2 (Melanotan II)MT-2 Regulatory Status
- IGF-1 LR3IGF-1 LR3 Regulatory Status
- GlutathioneGlutathione Regulatory Status
- NAD+NAD+ Regulatory Status
- KPVKPV Storage and Handling